Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease

Neuropharmacology

Volumn 59, Issue 4-5, 2010, Pages 295-302

  Bales, Kelly R ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer disease; Amyloid; Apolipoprotein E; Neuronal lipid

Indexed keywords

AMYLOID BETA PROTEIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIVER X RECEPTOR; PROBUCOL;

ACTION POTENTIAL; ALZHEIMER DISEASE; BRAIN FUNCTION; CLINICAL TRIAL; DRUG WITHDRAWAL; DYSLIPIDEMIA; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOME ANALYSIS; GLIA CELL; GLUCOSE METABOLISM; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BRAIN LEVEL; LIPID METABOLISM; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; QT PROLONGATION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; CELL MEMBRANE; HOMEOSTASIS; HUMANS; LIPID METABOLISM;

EID: 77955921493     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.01.005     Document Type: Review

References (85)

1. Agosta F., Vossel K.A., Miller B.L., Migliaccio R., Bonasera S.J., Filippi M., Boxer A.L., Karydas A., Possin K.L., Gorno-Tempini M.L. Apolipoprotein E e{open}4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2018-2022.
2. Alexander G.E., Chen K., Pietrini P., Rapoport S.I., Reiman E.M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 2002, 159:738-745.
3. Bales K.R., Verina T., Dodel R.C., Du Y., Altsteil L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J., Piccardo O., Ghetti B., Paul S.M. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997, 17:263-264.
4. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel R.C., Saura J., Fishman C.E., DeLong C.A., Piccardo P., Petegnief V., Ghetti B., Paul S.M. Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:15233-15238.
5. Bales K.R., Liu F., Koger D., Wu S., Mabry T., Christie M., Cao G., Paul S.M. Apolipoprotein E-isoform dependent decrease in brain β-amyloid following treatment of PDAPP transgenic mice with a LXR agonist. Soc. Neurosci. Abstr. 2008, 45.14.
6. Bales K.R., Liu F., Wu S., Lin S., Koger K., DeLong C., Hansen J., Sullivan P.M., Paul S.M. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J. Neurosci. 2009, 29:6771-6779.
7. Beffert U., Cohn J.S., Petit-Turcotte C., Tremblay M., Aumont N., Ramassamy C., Davingnon J., Poirier J. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999, 843:87-94.
8. Borghini I., Barja F., Pometta D., James R.W. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim. Biophys. Acta 1995, 1255:192-200.
9. Boumzbeur F., Mason G.F., de Graaf R., Behar K.L., Cline G.W., Shulman G.I., Rothman D.L., Petersen K.F. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J. Cereb. Blood Flow September (Epub ahead of print) 2010, 30:211-221.
10. Boyles J.K., Pitas R.E., Wilson E., Mahley R.W., Taylor J.M. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmylinating glia of the peripheral nervous system. J. Clin. Invest. 1995, 76:1501-1513.
11. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009, 10:333-344.
12. Buckner R.L. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 2004, 44:195-208.
13. Caselli R.J., Chen K., Lee W., Alexander G.E., Reiman E.M. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch. Neurol. 2008, 65:1231-1236.
14. Chen K., Reinman E.M., Alexander G.E., Caselli R., Gerkin R., Bandy D., Domb A., Osborne D., Fox N., Crum W.R., Saunders A.M., Hardy J. Correlations between apolipoprotein E e{open}4 gene dose and whole brain atrophy rates. Am. J. Psychiatry 2007, 164:916-921.
15. Corder E.H., Saunders A.M., Risch N.J., Strittmater W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994, 7:180-184.
16. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 1990, 27:457-464.
17. Demeester N., Castro G., DeGeitere C., Fruchart J.C., Santens P., Mulleners E., Engelborghs S., DeDeyn P.P., Vanderkerckhove J., Rosseneu M., Labeur C. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferease in CSF of normal individuals and patients with Alzheimer's disease. J. Lipid Res. 2000, 41:963-974.
18. Dennis, N.A., Browndyke, J.N., Stokes, J., Need, A., Burke, J.R., Welsh-Bohmer, K.A., Cabeza, R., 2009. Temporal lobe functional activity and connectivity in young adult APOE e{open}4 carriers. Alzheimer's & Dementia. in press. doi:10.1016/j/jalz.2009.07.003.
19. DeMattos R.B. Apolipoprotein E dose-dependent modulation of β-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci. 2004, 23:255-262.
20. Dietschy J.M., Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 2001, 12:105-112.
21. Dietschy J.M. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol. Chem. 2009, 390:287-293.
22. Fagan A.M., Younkin L.H., Morris J.C., Fryer J.D., Cole T.G., Younkin S.G., Holtzman D.M. Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann. Neruol. 2000, 48:201-210.
23. Fagan A.M., Mintun M.A., Mach R.H., Lee S.-Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 2005, 59:512-519.
24. Fan J., Donkin J., Wellington C. Greasing the wheels of Aβ clearance in Alzheimer's disease: the role of lipids and apolipoprotein E. BioFactors 2009, 35:239-248.
25. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997, 278:1349-1356.
26. Filippini N., MacIntosh B.J., Hough M.G., Goodwin G.M., Frisone G.B., Smith S.M., Matthews P.M., Beckmann C.F., MacKay C.E. Distinct patterns of brain activity in young carriers of the APOE e{open}4 allele. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7209-7214.
27. Greenberg S.M., Rebeck G.W., Vonsattel J.P., Gomez-Isla T., Hyman B.T. Apoplipoprotein E episolon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 1995, 38:254-259.
28. Grootendorst J., Bour A., Vogel E., Kelche C., Sullivan P.M., Dodart J.-C., Bales K.R., Mathis C. Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. Behav. Brain Res. 2005, 159:1-14.
29. Hardy J.A., Higgins G.A. Alzheimer disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
30. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
31. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006, 52:3-13.
32. Hedden T., Van Dijk K.R.A., Becker A.J., Mehta A., Sperling R.A., Johnson K.A., Buckner R.L. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J. Neurosci. 2009, 29:12686-12694.
33. Herz J., Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat. Rev. Neurosci. 2006, 7:850-859.
34. Hirsch-Reinshagen V., Wellington C.L. Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr. Opin. Lipidol. 2007, 18:325-332.
35. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Satorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:2892-2897.
36. Hyman B.T., West H.L., Rebeck G.W., Buldyrev S.V., Mantegna R.N., Ukleia M., Havlin S., Stanley H.E. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc. Natl. Acad. Sci. U.S.A. 1995, 92:3586-3590.
37. Irizarry M.C., Rebeck G.W., Cheung B., Bales K.R., Paul S.M., Holtzman D.M., Hyman B.T. Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background. Ann. N. Y. Acad. Sci. 2000, 920:171-178.
38. Ji Y., Gong Y., Gan Y., Beach T., Hotlzman D.M., Wisniewski T. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patient. Neuroscience 2003, 122:305-315.
39. Kim J., Basak J., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
40. Klunk W.E., Engler H., Norberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savicheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 2004, 55:306-319.
41. Kockyx M., Jessup W., Kritharides L. Regulation of endogenous apolipoprotein E secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1060-1067.
42. Koudinov A.R., Temirbolat T.T., Koudiova N.V. The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implications for brain cholesterol pathology?. Neurosci. Lett. 2001, 314:115-118.
43. Larson E.B., Shadlen M., Wang L., McCormick W.C., Bowen J.D., Teri L., Kukull W.A. Survival after initial diagnosis of Alzheimer disease. Ann. Int. Med. 2004, 140:501-509.
44. Liang Y., Lin S., Beyer T.P., Zhang Y., Wu X., Bales K.R., DeMattos R.B., May P.C., Li S.D., Jiang X.-C., Eacho P.I., Cao G., Paul S.M. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion, and cholesterol homeostasis in astrocytes. J. Neurochem. 2004, 88:623-634.
45. Mauch D.H., Nagler K., Schumacher S., Goritz C., Muller E.C., Otto A., Pfrieger F.W. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001, 294:1354-1357.
46. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
47. Morikawa M., Fryer J.D., Sullivan P.M., Christopher E.A., Wahrle S.E., DeMattos R.B., O'Dell M.A., Fagan A.M., Lashuyel H.A., Wlaz T., Asai K., Holtzman D.M. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β. Neurobiol. Dis. 2005, 19:66-76.
48. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts Aβ but not Tau Alzheimer's pathology in cognitively normal aging. Arch. Neurol 2009, 66:1469-1475.
49. Mueller S.G., Weiner M.W. Selective effect of age, Apo e{open}4, and Alzheimer's disease on hippocampal subfields. Hippocampus 2009, 19:558-564.
50. Nicoll J.A., Roberts G.W., Graham D.I. Amyloid β-peptide, APOE genotype and head injury. Ann. N. Y. Acad. Sci. 1996, 777:271-275.
51. Ohm T.G., Kirca M., Bohl J., Scharnagl H., Groβ W., Marz W. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995, 3:585-587.
52. Poirier J. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. Alzhemiers Demen. 2008, 4:S91-S97.
53. Pfrieger F.E.W. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes?. Bioessays 2003, 25:72-78.
54. Prince J.A., Zetterberg H., Andreasen N., Marcusson J., Blennow K. APOE e{open}4 allele is associated with reduced cerebrospinal fluid levels of Aβ42. Neurology 2004, 62:2116-2118.
55. Ramaswamy G., Xu Q., Huang Y., Weisgraber K. Effect of domain interaction on apolipoprotein E levels in mouse brain. J. Neurosci. 2005, 25:10658-10663.
56. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele of apolipoprotein E. N. Engl. J. Med. 1996, 334:752-758.
57. Reiman E.M., Caselli R.J., Chen K., Alexander G.E., Bandy D., Frost J. Declining brain activity in cognitively normal apolipoprotein E e{open}4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:3334-3339.
58. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:284-289.
59. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Correlations between apolipoprotein E e{open}4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8299-8302.
60. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B.S., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., Caselli R.J. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6820-6825.
61. Riddell D.R., Zhou H., Comery T.A., Kouranova E., Lo C.F., Warwick H.K., Ring R.H., Kirksey Y., Aschmies S., Xu J., Kubek K., Hirst W.D., Gonzales C., Chen Y., Murphy E., Leonard S., Vasylyev D., Oganesian A., Martone R., Pangalos M., Reinhart P.H., Jacobsen J.S. The LXR agonist T0901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 2007, 34:621-628.
62. Riddell D.R., Zhou H., Atchison K., Warwick H.K., Atkinson P.J., Jefferson J., Xu L., Aschmies S., Kirksey Y., Hu Y., Wagner E., Parratt A., Xu J., Li Z., Zaleska M.M., Jacobsen J.S., Pangalos M.N., Reinhart P.M. Impact of apoplipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 2008, 28:11445-11453.
63. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., Hulette C., Crain B., Goldgaber D., Roses A.D. Association of apolipoprotein allele e{open}4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43:1467-1472.
64. Scheff S.W., Price D.A. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol. Aging 2003, 24:1029-1046.
65. Scheff S.W., Price D.A., Schmitt F.A., Mufson E.J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2006, 27:1372-1384.
66. Schuff N., Woerner N., Boreta L., Kornfield T., Shaw L.M., Trojanowski J.Q., Thompson P.M., Jack C.R., Weiner M.W., the Alzheimer's Disease Neuroimaging Initiative MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2008, 132:1067-1077.
67. Schmechel D.E., Saunders A.M., Strittmater W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:9649-9653.
68. Shobal L.A., Hsiung G.-Y.R., Feldoman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005, 4:841-852.
69. Sluimer J.D., Vrenken H., Blankenstein M.A., Fox N.C., Scheltens P., Barkhof F., van der Fleir W.M. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology 2008, 70:1836-1841.
70. Sperling R.A., LaViolette P.S., O'Keefe K., O'Brien J., Rentz D.M., Pihlajamaki M., Marshall G., Hyman B.T., Selkoe D.J., Hedden T., Buckner R.L., Becker J.A., Johnson K.A. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009, 63:178-188.
71. Strimatter W.J., Saunders A.M., Schmechel D., Pericak,-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:1977-1981.
72. Strimatter W.J., Roses A.D. Apolipoprotein E and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1995, 9:4725-4727.
73. Sullivan P.M., Mezdour H., Aratani A., Knouff C., Najib J., Reddick R.L., Quarfordt S.H., Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 1997, 29:17972-17980.
74. Sullivan, P.M., Han, B., Liu, F., Mace, B.E., Ervin, J.F., Wu, S., Koger, D., Paul, S.M., Bales, K.R. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol. Aging, in press. doi:10.1016/j.neurobiolaging.2009.05.011.
75. Tannenberg R.K., Scott H.L., Tannenberg A.E.G., Doss P.R. Selective loss of proteins in Alzheimer's disease: evidence for an increased severity with APOE e{open}4. Neurochemistry 2006, 49:631-639.
76. Teasdale G.M., Nicoll J.A., Murray G., Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997, 350:1069-1071.
77. Trommer B.L., Shah C., Yun S.H., Gamkrelidze G., Pasternak E.S., Ye G.L., Sotak M., Sullivan P.M., Pasternak J.F., LaDu M.J. ApoE isoform affects LTP in human targeted replacement mice. Neuroreport 2004, 15:2655-2658.
78. Wahrle S.E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C.L., Bales K.R., Paul S.M., Holtzman D.M. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 2008, 118:671-682.
79. Walker L.C., Pahnke J., Madauss M., Vogelgesang S., Pahnke A., Herbst E.W., Stausske D., Walther R., Kessler C., Warzok R.W. Apolipoprotein E4 promotes the early deposition of Aβ42 and then Aβ40 in the elderly. Acta Neuropathol. 2000, 100:36-42.
80. Wang C., Wilson W.A., Moore S.D., Mace B.E., Maeda N., Schmechel D.E., Sullivan P.M. Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol. Dis. 2005, 18:390-398.
81. Weisgraber K.H. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 1994, 45:249-301.
82. Wishart H.A., Saykin A.J., McAllister T.W., Rabin L.A., McDonald B.C., Flashman L.A., Roth R.M., Mamourian A.C., Tsonglais G.J., Rhodes C.H. Regional brain atrophy in cognitively intact adults with a single APOE e{open}4 allele. Neurology 2006, 67:1221-1224.
83. Xu Q., Li Y., Cyras C., Sanan D.A., Cordell B. Isolation and characterization of apolipoproteins from murine microglia. J. Biochem. 2000, 275:31770-31777.
84. Xu P.-T., Li Y.-J., Qin X.-J., Kroner C., Odlum-Green A., Xu H., Wang T.Y., Schmechel D.E., Hulette C.M., Ervin J., Hauser M., Haines J., Pericak-Vance M.A., Gilbert J.R. A SAGE study of apolipoprotein E3/3, E3/4, and E4/4 allele-specific gene expression in hippocampus of Alzheimer disease. Mol. Cell. Neurosci. 2007, 36:313-331.
85. Zhong N., Ramaswamy G., Weisgraber K.H. Apolipoprotein E4 domain interaction induces endoplasmic reticulum stress and impairs astrocyte function. J. Biol. Chem. 2009, 284:27273-27280.